Poster Session A: Tuesday - Wednesday morning

A01: CQA Testing Across the mRNA Development Journey, Presented by Jessika W., AnaBioTec

A02: Picodroplets for Biologics Discovery and Cell Line Development: Accelerating the Discovery and Development Process, Presented by Frank G., Sphere Fluidics

A03: Quantification of the Antigen Density Activation Threshold for Targeted Immunotherapeutics, Presented by Lotta H., Antibody Analytics

A04: Primary Human Immune Cell Assays for the Evaluation of New Immuno-Oncology Therapies, Presented by Shatakshi S., Antibody Analytics

A05: Systematic Identification of Cancer Neoantigens Derived from Neo-Open Reading frame Peptides (NOPs), Presented by Renee S., CureVac Netherlands B.V.

A06: Precision Tumor-on-a-Chip Model for Intravenous Drug and Immune Cell Delivery, Presented by Sebastien M., Finnadvance Aapistie

A07: AI-Powered Solutions for T-Cell Monitoring in Cancer Vaccine Research, Presented by Tom B., ImmuneWatch

A08: Collagen Binding TNF Reduces Systemic Toxicity and Drives Complete Remission of Established Immunologically Cold Murine Tumours, Presented by Pooja K., Imperial College London

A09: Endothelial PD-L1 Influences CD8+ T Cell Cytotoxicity, Thereby Altering Tumor Growth in Non-Small Cell Lung Cancer, Presented by Anh-Co T., Katholieke Universiteit Leuven

A10: Fully Human Heavy Chain Only Antibody-Based mRNA-Encoded T Cell Engager for Cancer Immunotherapy, Presented by Erica F., Nona Biosciences

A11: A Direct CAR-Based Library Screening Platform to Develop Fully Human Heavy Chain Only CAR-T Cell Therapies, Presented by Xiangyu R., Nona Biosciences

A12: Cutting-Edge HCAb Harbour Mice® Platform to Generate Fully Human Heavy Chain Only Antibodies, Presented by Jiyong Z., Nona Biosciences

A13: A Phase I Dose Escalation and Expansion Trial of LYT-200, a Galectin-9 Antibody, in Solid Tumors and AML, Presented by Aleksandra F., PureTech Health

A14: Enhancing T Cell-Centred Cancer Vaccination Therapies through Rational Epitope Design and In Vitro Validation, Presented by Julian F., Sanquin

A15: Inhibition of TREX1 Increases Interferon Signaling and Reduces Tumor Growth In Vivo, Presented by Camilla S., Sprint Bioscience AB

A16: The SARS-CoV-2 Spike Protein Induces Lung Cancer Migration and Invasion in a TLR2-Dependent Manner, Presented by Jiyoung K., Sungkyunkwan University

A17: CXCR5 and TLR4 Signals Synergistically Enhance Non-Small Cell Lung Cancer Progression, Presented by Ji Hye S., Sungkyunkwan University

A18: Development of a New Vaccination Strategy with Artificial Synthetic Long Peptides (aSLP) in Melanoma, Presented by Amelie G., University of Nantes

A19: Multi-Functional Antibodies' Potential to Improve Efficacy and Overcome Resistance in Cancer Therapy, Presented by Pär N., Karolinska Institute



Poster Session B: Wednesday afternoon - Thursday

B01: A Trispecific Albumin-Based Checkpoint Inhibitor T-Cell Engager Design for Combinatorial Immunotherapy, Presented by Elisabeth F., Aarhus University

B02: Fully Human Conditional Agonist 4-1BB×CD40 Bispecific Antibody Exhibits Potent In Vitro and In Vivo Efficacy, Presented by Yong X., Biocytogen Boston Corporation

B03: Arming Monoclonal Antibodies with Cytotoxic Peptides for Cancer Treatment, Presented by Izaskun M., Biofisika Institute

B04: Development of a Novel Antibody/Membrane Hybrid-Based Platform for Drug Delivery, Presented by Edurne R., Biofisika Institute

B05: Large-Scale Characterization of Drug Candidates Against Transmembrane Receptors Using HT-SPR, Presented by Andrew G., Carterra

B06: High Throughput Vascularization-on-Chip for Inflammation Studies and Immune Cell Migration Assays, Presented by Pauliina J., Finnadvance Aapistie

B07: AI/ML-Ab™ (Aim-Lab): AI Assisted De-Novo Design and Discovery, Presented by Christopher K., Fusion Antibodies

B08: Immunotoxicity Assessment of Clinical Antibodies Using Ex Vivo Whole Blood Assay (ID.Flow®), Presented by Sakthi S., Immuneed

B09: Translational Humanized Models for Immunotherapy Drug Development, Presented by Philip G., Jackson Laboratory

B10: A Vascularized Melanoma Model with Unidirectional Perfusion of Circulating Immune Cells for Advancing Immune-Oncology Research, Presented by Luuk D., MIMETAS

B11: Integrated Modeling of T Cell Repertoires to Identify Clonotype Signatures of ICI Response, Presented by Vijay V., Omniscope

B12: NK Humanized Mouse Models for the In Vivo Evaluation of Anti-Tumor NK-Cell Therapies, Presented by Pauline R., Sanofi R&D

B13: Facilitating Combination Therapy Studies in Patient-Derived 3D Tumour Models, Presented by Karla P., ScreenIn3D

B14: Oncolytic Adenovirus Armed with Human Mucin1 T Cell Engager and Interleukin-2 Potentiates Antitumor T Cell Responses, Presented by Saru B., University of Helsinki

B15: Differential Impact of PD-1 or TIGIT Genetic Deletion in Melanoma-Specific CD8+ T Lymphocytes, Presented by Gwenann C., University of Nantes

B16: Selective Bi-Specific Engagement: Exploiting Monovalent vs Bivalent Antibody Binding, Presented by Rachel D., University of Strathclyde

B17: Efficacy of aßT-Cell Based Immunotherapies Rely on CCR5 Expression in Both CD4+ and CD8+ aßT Cells, Presented by Lucrezia G., University Medical Center Utrecht

B18: Improving the Potency of Gamma Delta TCR Anti-CD3 Bispecific T Cell Engagers (GABs) Using CD3 Binding Affinity Properties, Presented by Mara N., University of Utrecht

B19: Armoring CAR-T Therapy with PD-1 Blockade: A Powerful Strategy for Enhancing Anti-Tumor Effects in Pancreatic Cancer, Presented by Armelle LD., Wuxi Apptec UK Ltd.

B20: Using Surface Plasmon Resonance to Investigate the Multi-Specific Modalities of Immunotherapeutic MoleculesPresented by Courteney, Antibody Analytics






Register Now

Modulating the Tumour Microenvironment